Neuropeptide Y and its Y2 receptor: potential targets in neuroblastoma therapy.

Oncogene · 2010 · PMC2955165 · PMID 20676138

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

Moreover, Y2R antagonist-treated SK-N-BE(2) xenografts appeared to have lower vascularization, as measured by the number of arteries per cm 2 , though differences did not reach statistical significance ( Fig. 5B ).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.